China
Africa
Explore chapters and articles related to this topic
Diseases of the Peripheral Nerve and Mononeuropathies
Published in Philip B. Gorelick, Fernando D. Testai, Graeme J. Hankey, Joanna M. Wardlaw, Hankey's Clinical Neurology, 2020
Diana Mnatsakanova, Charles K. Abrams
Eosinophilic granulomatosis with polyangiitis syndrome usually presents with asthma, pulmonary infiltrates, fevers, and eosinophilia. However, an initial presentation of vasculitic neuropathy occurs in more than 20% of cases.
Paper 2
Published in Amanda Rabone, Benedict Thomson, Nicky Dineen, Vincent Helyar, Aidan Shaw, The Final FRCR, 2020
Amanda Rabone, Benedict Thomson, Nicky Dineen, Vincent Helyar, Aidan Shaw
Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss) can also cause arthralgia and rashes but is not associated with the other findings in this case and would also be associated with asthma and sinusitis.
Rheumatology
Published in Paul Bentley, Ben Lovell, Memorizing Medicine, 2019
Eosinophilic granulomatosis with polyangiitis (EGPA - formerly Churg–Strauss syndrome)Epi: Any age, M:F = 1.3:1PC: Asthma, mononeuritis multiplex, eosinophilia
Risks and treatment related aspects of COVID-19 infection in patients with ANCA-associated vasculitis
Published in Scandinavian Journal of Rheumatology, 2023
A Antovic, A Bruchfeld, J Ekland, B Lövström, A Hugelius, O Börjesson, A Knight, I Gunnarsson
In a collaborative project between the Departments of Nephrology and Rheumatology at Karolinska University Hospital in Stockholm and the Department of Rheumatology at Uppsala University Hospital, AAV patients were previously included in large research cohorts. The occurrence and consequences of COVID-19 were retrieved from medical records or the Swedish Rheumatology Registry from March 2020 to January 2021 (Karolinska) and to May 2021 (Uppsala) for living patients in these cohorts (n = 310). Patients diagnosed with granulomatosis with polyangiitis (n = 232), microscopic polyangiitis (n = 56), or eosinophilic granulomatosis with polyangiitis (n = 22) were included. The eligibility criteria were the Chapel Hill Consensus Conference 2012 definitions, and a current or prior positive test for proteinase-3 (PR3)- or myeloperoxidase (MPO)-ANCA or the European Medicines Agency (EMA) classification (6, 7). The Swedish Ethical Review Authorities approved the study.
Ustekinumab associated chronic eosinophilic pneumonia
Published in Journal of Asthma, 2021
Saminder Singh Kalra, Mwelwa Chizinga, Cesar Trillo-Alvarez, Eric S. Papierniak
Bronchoscopy with BAL of the left lower lobe, anterior segment, was performed and demonstrated normal airway anatomy and bronchial mucosa with minimal secretions. Her BAL cell count was significantly abnormal with 63% eosinophils, 19% monocytes, 17% polymorphs, and 2% lymphocytes. Because of her prior history of asthma and sinus disease, one of the initial diagnostic considerations was eosinophilic granulomatosis with polyangiitis (EGPA). Her ANCA serology was negative and a biopsy of the nasal mucosa showed normal sinonasal tissue with squamous metaplasia and the absence of vasculitis/granulomata or eosinophils. Based on a lack of evidence for EGPA or other autoimmune conditions, along with a negative infectious workup, the patient was diagnosed with chronic eosinophilic pneumonia secondary to ustekinumab, and the drug was stopped. She was started on a tapering dose of prednisone 0.5 mg/kg daily
New biologics for allergic diseases
Published in Expert Review of Clinical Immunology, 2018
Laurie A. Manka, Michael E. Wechsler
Biologic medications for allergic diseases have predominantly targeted the Th-2 inflammatory pathway.Biologic medications approved for severe asthma include anti-IgE and anti-IL 5 therapies.Biologic medications approved for atopic dermatitis include anti-IL 4/IL-13 therapy.No biologic medications have been approved for chronic rhinosinusitis with nasal polyposis, but anti-IgE and anti-IL 5 therapies are under investigation.Biologic medications approved for chronic idiopathic urticaria include anti-IgE therapy.No biologic medications have been approved for eosinophilic esophagitis, but anti-IL 5 therapies are under investigation.Biologic medications approved for eosinophilic granulomatosis with polyangiitis include anti-IL 5 therapy.